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Activation of the sympathetic nervous system (SNS) has an important role in the
pathogenesis of hypertension, and is determined by the brain. Previous many studies
have demonstrated that oxidative stress, mainly produced by angiotensin II type 1 (AT1)
receptor and nicotinamide adenine dinucleotide phosphate (NAD (P) H) oxidase, in the
autonomic brain regions was involved in the activation of the SNS of hypertension. In
this concept, we have investigated the role of oxidative stress in the rostral ventrolateral
medulla (RVLM), which is known as the cardiovascular center in the brainstem, in the
activation of the SNS, and demonstrated that AT1 receptor and NAD (P) H oxidase-induced
oxidative stress in the RVLM causes sympathoexcitation in hypertensive rats. The
mechanisms in which brain oxidative stress causes sympathoexcitation have been
investigated, such as the interactions with nitric oxide (NO), effects on the signal
transduction, or inflammations. Interestingly, the environmental factors of high salt intake
and high calorie diet may also increase the oxidative stress in the brain, particularly in
the RVLM, thereby activating the central sympathetic outflow and increasing the risk of
hypertension. Furthermore, several orally administered AT1 receptor blockers have been
found to cause sympathoinhibition via reduction of oxidative stress through the inhibition
of central AT1 receptor. In conclusion, we must consider that AT1 receptor and the related
oxidative stress production in the brain cause the activation of SNS in hypertension, and
that AT1 receptor in the brain could be novel therapeutic target of the treatments for
hypertension.
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INTRODUCTION
Recentmany studies have suggested that sympathetic nervous sys-
tem (SNS) is important in the pathogenesis, initial pathological
events, development, and end organ damages of hypertension
(Grassi, 2009, 2010; Esler, 2010; Grassi et al., 2010; Mauo et al.,
2010). The activation of the SNS is determined by brain, espe-
cially by a rostral ventrolateral medulla (RVLM) in the brainstem
(Dampney, 1994; Guyenet, 2006). The RVLM neurons deter-
mine the basal central sympathetic outflow and integrate the
inputs from baroreceptors, chemoreceptors, and visceral recep-
tors via the nucleus of the solitary tract (NTS) (Pilowsky and
Goodchild, 2002; Dampney et al., 2003; Sved et al., 2003; Campos
and Bergamschi, 2006; Guyenet, 2006; Carlson and Wyss, 2008),
and it also receives the inputs from the paraventricular nucleus
(PVN) of the hypothalamus, which is known as a key nucleus of
the central cardiovascular regulation (Pilowsky and Goodchild,
2002; Dampney et al., 2005; Coote, 2007). Therefore, RVLM is
known as a cardiovascular center.
The importance of systemic oxidative stress has already been
determined in the various aspects of hypertension (Briones and
Touyz, 2010). There are several studies with regard to the role
of brain oxidative stress in the activation of the SNS and hyper-
tension (Tai et al., 2005; Peterson et al., 2006; Hirooka, 2008,
2011; Campos, 2009; Hirooka et al., 2010, 2011). Among them,
we have investigated the role of oxidative stress in the brain, par-
ticularly in the RVLM, in the pathogenesis of hypertension (Kishi
et al., 2004, 2008, 2009, 2010a,b, 2011a, 2012a,b; Koga et al., 2008;
Konno et al., 2008, 2012; Nozoe et al., 2008; Kishi and Sunagawa,
2011, 2012; Nishihara et al., 2012). Other investigators have also
confirmed our initial observations, and other details have been
further investigated. In this review, we describe the importance of
oxidative stress in the brainstem, particularly in the RVLM, on the
regulation of the SNS and its contribution to the pathophysiology
of hypertension.
OXIDATIVE STRESS IN THE RVLM CAUSES
SYMPATHOEXCITATION IN HYPERTENSIVE RATS
We have demonstrated that oxidative stress in the RVLM
is increased and contributes to the neural mechanisms of
hypertension in stroke-prone spontaneously hypertensive rats
(SHRSPs) (Kishi et al., 2004, 2008, 2009, 2010b, 2012a,b; Kishi
and Sunagawa, 2011, 2012) and spontaneously hypertensive
rats (SHRs) (Koga et al., 2008; Nishihara et al., 2012). We
also confirmed that a microinjection of tempol, a membrane-
permeable superoxide dismutase (SOD) mimetic, into the RVLM
decreased blood pressure and heart rate in SHRSPs, but not
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in normotensive rats. Furthermore, we transfected adenovirus
vectors encoding the MnSOD gene into the bilateral RVLM in
SHRSPs. Overexpression of MnSOD in the RVLM decreased
blood pressure, heart rate and urinary norepinephrine excre-
tion in SHRSPs, but not in normotensive rats. We also found
reduced SOD activity in the RVLM of SHRSPs compared with
normotensive rats, which led to a decreased capability of scaveng-
ing superoxide anions. Together, our these findings indicate that
oxidative stress in the RVLM increased blood pressure, which may
have occurred via an activation of the SNS, and this mechanism
was involved in the neural pathophysiology of hypertension in
SHRSPs. Consistent with our observations, it was reported that
increased superoxide anion in the RVLM contributed to hyper-
tension in SHRs (Tai et al., 2005). We have also demonstrated
that oxidative stress in the RVLM causes sympathoexcitaion in
other several hypertensive models, such as, salt-induced hyper-
tension (Koga et al., 2008), dietary-induced hypertension (Kishi
et al., 2011a; Konno et al., 2012), and experimental jet lag (Kishi
and Sunagawa, 2011). These results are consistent with previous
studies of other investigators (Fujita et al., 2007; Nagae et al.,
2009).
Interestingly, every intervention led to a similar extent of
reduction of blood pressure and superoxide production in hyper-
tensive rats. In our studies, the reduction of oxidative stress in the
RVLM causes prominent sympathoinhibition. Overexpression of
MnSOD (Kishi et al., 2004; Nishihara et al., 2012), or microin-
jection of tempol (Kishi et al., 2004; Koga et al., 2008; Konno
et al., 2012) decreases the activation of the SNS with reduction of
the oxidative stress in the RVLM. In addition, Oliveira-Sales et al
suggested that sympathoexcitation in renovascular (two-kidney
one-clip) hypertensive rats are associated with oxidative stress
in the RVLM and PVN of the hypothalamus and with systemic
oxidative stress (Oliveira-Sales et al., 2008, 2009). Because, the
two-kidney and one-clip model is an angiotensin II-dependent
hypertension model, it is not surprising that oxidative stress
was increased in this model. However, it is important that the
increased oxidative stress in the autonomic brain regions, such
as, the RVLM and PVN of the hypothalamus, was involved in the
activation of the SNS as one of themechanisms of hypertension in
this model. Moreover, a recent study found that oxidative stress in
the RVLM had a major role in the enhanced central sympathetic
outflow in the two-kidney one-clip hypertensive rats (Oliveira-
Sales et al., 2010a). These results strongly suggest that the increase
in oxidative stress in the RVLM is an important cause, not result,
of the sympathoexcitation, which leads to hypertension.
SOURCES OF OXIDATIVE STRESS IN THE RVLM
As the sources of oxidative stress production in the brain, there are
several candidates, such as, nicotinamide adenine dinucleotide
phosphate (NAD (P) H) oxidase, xanthine oxidase, uncoupled
nitric oxide synthase, and mitochondria (Hirooka, 2008, 2011;
Hirooka et al., 2010, 2011). Among them, we demonstrated that
the activation of the NAD (P) H oxidase through angiotensin II
type 1 (AT1) receptor had a major role in the oxidative stress pro-
duction in the RVLM of SHRSPs (Nozoe et al., 2008; Kishi et al.,
2010a, 2012b). Regional expression of the NAD (P) H oxidase has
been demonstrated in the brain including the NTS and RVLM
(Infanger et al., 2006; Campese et al., 2007; Bai et al., 2009).
Peripheral slow-pressor dose of angiotensin II in mice led to a
gradual development of hypertension that was correlated with
marked elevation in superoxide production (Zimmerman et al.,
2004b). In this case, the authors emphasized the importance of
the sub-fornical organ (SFO), in which the blood-brain barrier is
lacking and AT1 receptor is rich. Angiotensinergic inputs in the
SFO are delivered to the PVN of the hypothalamus, and then it
sends the neural information to the RVLM neurons. Thus, the
functional responses of the SFO to angiotensin II are the increases
in drinking behavior and blood pressure via the activation of the
SNS and vasopressin release. In addition, we showed that Rac1
activation occurs in the activation of NAD (P) H oxidase (Nozoe
et al., 2007; Hirooka et al., 2010; Kishi et al., 2010b). Rac1 is a
small G protein involved in integrating the intracellular trans-
duction pathways toward NAD (P) H activation and requires
lipid modifications to migrate from the cytosol to the cell mem-
brane. The inhibition of Rac1 caused by the transfection of the
adenovirus vectors encoding a dominant negative Rac1 into the
RVLM or NTS decreased blood pressure, heart rate and urinary
norepinephrine excretion in SHRSPs, but not in normotensive
rats (Nozoe et al., 2007; Hirooka et al., 2010). The blockade of
Rac1 translocation from cytosol to membrane in the RVLM of
SHRSPs causes sympathoinhibition via inhibition of NAD (P) H
oxidase and oxidative stress (Kishi et al., 2010b). It was demon-
strated that Nox2-containing NAD (P) H oxidase followed by an
influx of Ca2+ via the L-type calcium channels was the source
of the angiotensin II-induced oxidative stress production in the
NTS neurons that were anterograde labeled from the vagal affer-
ents (Wang et al., 2004, 2006). Because, azelnidipine could reduce
oxidative stress in the RVLM of SHRSPs associated with sympa-
thoinhibition, the inhibition of the Ca2+ channel in the RVLM
may have reduced oxidative stress (Konno et al., 2008; Shinohara
et al., 2012) Thus, our findings indicate that the activation of
the Rac1 in the RVLM or NTS produces oxidative stress via the
NAD (P) H oxidase in SHRSPs. In fact, it was demonstrated that
the activation of the Rac1/NAD (P) H oxidase was required in
the pressor and dipsogenic actions of angiotensin II in the brain
(Zimmerman et al., 2004a)
The brain renin-angiotensin system is activated in hyperten-
sion and chronic heart failure with enhanced central sympathetic
outflow (Hu et al., 2002; Reja et al., 2006; Leenen, 2007; Huang
and Leenen, 2009; Zucker et al., 2009; Dupont and Brouwers,
2010) Aldosterone increases angiotensin-converting enzyme, AT1
receptor and oxidative stress in the PVN of the hypothala-
mus of salt-sensitive hypertension and ischemic heart failure
(Huang et al., 2011). It has been determined that mitochondria-
derived oxidative stress mediates sympathoexcitation induced by
angiotensin II in the brain (Nozoe et al., 2007; Zimmerman
and Zucker, 2009). Exogenously administered angiotensin II into
the RVLM elicits the pressor response via activation of the SNS
(Hirooka et al., 1997; Dampney et al., 2007) The inhibition of AT1
receptor in the RVLM by an AT1 receptor blocker reduces blood
pressure with sympathoinhibition in hypertensive rats (Hirooka
et al., 1997; Koga et al., 2008; Kishi et al., 2010a, 2011a, 2012a,b;
Konno et al., 2012). We found that the overexpression of MnSOD
attenuated the angiotensin II-induced pressor response and also
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suppressed the angiotensin II-induced oxidative stress produc-
tion in the RVLM (Nozoe et al., 2008) A recent study also
demonstrated that the oxidative stress-induced impairment of the
mitochondrial electron transport chain complexes in the RVLM
contribute to further chronic oxidative stress, thereby leading to
augmented central sympathetic outflow and hypertension (Chan
et al., 2009). All these results indicate that AT1 receptor/NAD (P)
H oxidase would be a main source to produce the oxidative stress
in the RVLM of hypertensive rats.
MECHANISMS OF BRAIN OXIDATIVE STRESS-INDUCED
SYMPATHOEXCITATION
There is an interaction between superoxide and nitric oxide (NO).
In the brain, NO inhibits the activation of the SNS (Kishi et al.,
2001, 2002; Patel et al., 2001; Hirooka et al., 2003). We found
that an increase in NO in the RVLM reduces blood pressure,
heart rate, and the activation of the SNS in normotensive rats
and SHRSPs (Kishi et al., 2001, 2002), and the magnitude of the
decreases in these variables were greater in SHRSPs than in nor-
motensive rats, suggesting a deficiency in the NO bioavailability
in SHRSPs. There is a possibility that the deficiency in the NO
bioavailabilitymight be induced by oxidative stress. Furthermore,
we demonstrated that that overexpression of inducible NO syn-
thase (iNOS) in the RVLM elicited blood pressure elevation and
sympathoexcitation in normotensive rats via increase in oxida-
tive stress (Kimura et al., 2005). This may have been caused by
the so-called uncoupling of the NO synthase function because of
the deficiency of the precursor of L-arginine and/or the cofactor
tetrahydrobiopterin. Importantly, we have found that the iNOS
expression in the RVLM is enhanced in SHRs compared with nor-
motensive rats, and the microinjection of iNOS blockers into the
RVLM reduced blood pressure only in SHRs (Kimura et al., 2009).
A recent study also suggested that the up-regulation of AT1 recep-
tor and iNOS in the RVLMwas important for the maintenance of
high blood pressure and renal sympathetic activation in the two-
kidney one-clip hypertensive rats (Oliveira-Sales et al., 2010b).
In the relationship between superoxide and NO, we should
focus on the peroxynitrite formation, because the kinetics forma-
tion of peroxynitrite from superoxide and NO is strong (Zielonka
et al., 2012). Actually, peroxynitrite in the RVLM has an exci-
totoxic effect (Zanzinger, 2002). A recent study suggested that
reactive oxygen species and reactive nitrogen species, such as per-
oxynitrite, could dose-dependently regulate iNOS function, and
that peroxynitrite reduces both NO and superoxide production
via enzymatically iNOS dysfunction (Sun et al., 2010). Another
report indicated that an interactive action between NO and super-
oxide in the RVLM via formation of peroxynitrite contributes to
the un-sustained hypotensive effect of NO after overexpression of
endothelial NO synthase in SHRs (Kung et al., 2008). The role
of peroxynitrite from NO and superoxide in the brain on the
regulation of the SNS should be further examined.
In the brain, the balance between excitatory and inhibitory
amino acids determines the neural activity (Li et al., 2002;
Garthwaite, 2008). In hypertensive rats, inhibitory amino acid
γ-amino butylic acid (GABA) in the RVLM is decreased (Kishi
et al., 2002), which in part contributes to the activation of the
SNS. NO in the RVLM increases GABA release (Kishi et al.,
2001). We consider that oxidative stress would reduce the release
of GABA in the RVLM via deficiency in NO bioavailability,
which might cause sympathoexcitation. Interestingly, we recently
demonstrated that oxidative stress modulates the balance between
excitatory amino acid glutamate and GABA in the RVLM of
hypertensive rats (Nishihara et al., 2012).
We also have focused the signal transduction associated
with oxidative stress. AT1 receptor activates caspase-3 through
the Ras/mitogen-activated protein kinase/extracellular signal-
regulated kinase (ERK) in the RVLM, which is involved in the
sympathoexcitation in SHRSPs (Kishi et al., 2010a,b,c). The activ-
ities of Ras, p38 mitogen- activated protein kinase (MAPK),
ERK and caspase-3 in the RVLM were elevated in SHRSPs
compared with those in normotensive rats. The phosphoryla-
tion of the pro-apoptotic protein Bax and Bad, which releases
cytochrome c in the mitochondria, leads to caspase-3 activa-
tion (Kishi et al., 2010a,b,c). In contrast, the phosphorylation of
the anti-apoptotic protein Bcl-2 inhibits the caspase-3 activation.
Intracerebroventricular (ICV) infusion of a caspase-3 inhibitor
reduces blood pressure, heart rate and the activation of the SNS
in SHRSPs, but not in normotensive rats. ICV infusion of an
AT1 receptor blocker also reduced blood pressure, heart rate, and
activation of the SNS and also reduced the activities of Ras, p38
MAPK, ERK, and caspase-3 in the RVLM of SHRSPs, suggest-
ing that these pathways exist downstream to the AT1 receptor
activation in the RVLM of SHRSPs and are related to blood pres-
sure elevation and sympathoexcitation of SHRSPs. In support
of our findings, it was reported that the NAD (P) H oxidase
derived superoxide anion mediates the activation of p38 MAPK
or ERK but not the stress-activated protein kinase/Jun N-terminal
kinase by angiotensin II in the RVLM and pressor response (Chan
et al., 2005). Furthermore, in a later study, the authors sug-
gested that the activation of the NAD (P) H oxidase/ERK in the
RVLM induced the phosphorylation of the transcriptional factor
cyclic adenosine monophosphate response element-binding pro-
tein and c-fos induction, thereby contributing to the long-term
pressor response triggered by angiotensin II (Chan et al., 2007).
It is also important to note that the activation of the activator
protein 1 and the Jun N-terminal kinase may occur in rabbits
with rapid pacing-induced heart failure (Liu et al., 2006). Thus,
the signaling pathway followed by the oxidative stress production
may differ between hypertension and heart failure because of the
advancement of the disease state.
Recently, the further central mechanisms of sympathoexcita-
tion associated with oxidative stress are focused, such as, perivas-
cular macrophages in the brain (Yu et al., 2010; Hirooka, 2010),
neuron-astrocyte uncoupling (Kishi et al., 2010c, 2011b), tran-
scription factor NF-κB (Cardinale et al., 2011), or microglial
cytokines (Shi et al., 2010) in the brain causes sympathoexcitation
in hypertension and heart failure. Further studies are required to
clarify these mechanisms.
INFLUENCE OF SALT AND OBESITY ON OXIDATIVE STRESS
IN THE BRAIN AND SYMPATHETIC NERVE ACTIVITY
A high salt intake is an important environmental factor
for the development of hypertension (Adrogue and Madias,
2007). Increasing evidence suggests that central nervous system
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mechanisms are involved in salt-induced hypertension, although,
the kidney also has a key role in salt-induced hypertension
(Brooks et al., 2005; Huang et al., 2006; Adams et al., 2007;
Osborn et al., 2007). We also previously demonstrated that the
increased AT1 receptor and NAD (P) H oxidase expression lev-
els in the RVLM were responsible for the increased oxidative
stress production and blood pressure in SHRs with a high salt
intake compared with those with a regular salt intake (Koga et al.,
2008). Consistent with our findings, increased oxidative stress was
involved in the blood pressure elevation through an enhanced
central sympathetic outflow in Dahl salt-sensitive rats (Fujita
et al., 2007). It is possible that the enhanced neuronal activ-
ity in the PVN of the hypothalamus would augment the RVLM
neuronal activity in these concepts.
It has also been demonstrated that the activation of the SNS
has an important role in obesity-related hypertension, includ-
ing the metabolic syndrome (Landsberg, 2001; Rahmouni et al.,
2005; Esler et al., 2006; Grassi, 2006, 2007; Stocker et al., 2007).
Insulin or leptin increases the activation of the SNS in obesity or
metabolic syndrome (Rahmouni et al., 2005; Prior et al., 2010;
Hilzendeger et al., 2012). In addition, it has been demonstrated
that the RVLM neurons are activated in obesity-induced rats
(Stocker et al., 2007). A previous study suggested that oxidative
stress, particularly in the hypothalamus, was involved in the acti-
vation of the SNS in obesity-induced hypertensive rats (Nagae
et al., 2009). Recently, we also have demonstrated that AT1 recep-
tor/NAD (P) H oxidase-induced oxidative stress in the RVLM
causes sympathoexcitation in obesity-induced hypertensive rats
(Kishi et al., 2011a; Konno et al., 2012). Leptin is reported to
have an interaction with brain renin-angiotensin system in the
regulation of the SNS (Hilzendeger et al., 2012).
These findings with regard to the salt-induced and/or obesity-
induced hypertension strongly suggest that oxidative stress in
the RVLM is increased not only by gene background (such
as in SHRSPs or SHRs) but also by environmental factor. A
recent study reported the epigenetic alteration is occurred in salt-
induced hypertension (Mu et al., 2011). There is a possibility that
various genetic, environmental, and epigenetic factors affect the
brain and causes sympathoexcitation via oxidative stress in the
RVLM.
EFFECTS OF AT1 RECEPTOR BLOCKERS ON OXIDATIVE
STRESS IN THE BRAIN AND SYMPATHETIC NERVE
ACTIVITY
As described above, the up-regulation of AT1 receptor in the brain
has an important role in the pathophysiology of hypertension
(Sved et al., 2003; Guyenet, 2006; Dupont and Brouwers, 2010)
It is interesting to note that AT1 receptor is rich in the specific
brain, such as, anteroventral third ventricle, PVN of the hypotha-
lamus, NTS and RVLM in the brainstem (Allen et al., 1999;
Hu et al., 2002; McKinley et al., 2003; Reja et al., 2006). It has
been demonstrated that peripherally administered AT1 receptor
blockers could penetrate the blood-brain barrier and blocks AT1
receptor within the brain as well as outside of the brain, although,
the extent of the blocking action within the brain varies among
AT1 receptor blockers when they are administered peripherally
(Wang et al., 2003; Kishi et al., 2012b; Konno et al., 2012).
The peripheral treatment with AT1 receptor blockers attenuates
or nearly blocks the pressor response to centrally administered
angiotensin II (Tsuchihashi et al., 1999; Nishimura et al., 2000;
Gohlke et al., 2001; Kishi et al., 2012b; Konno et al., 2012) This
is also observed with the microinjection of angiotensin II into
the RVLM in SHRs orally treated with olmesartan (Lin et al.,
2005). Furthermore, the central nervous system blockade by the
peripheral administration of AT1 receptor blockers has been doc-
umented by autoradiographic binding studies (Wang et al., 2003).
It should be noted that the high density of AT1 receptor is present
in brain regions that are involved in the regulation of the SNS
such as the circumventricular organs (for example, the SFO, the
organum vasculosum laminae terminalis, and area postrema)
outside of the blood-brain barrier where peripherally adminis-
tered AT1 receptor blockers are able to access without considering
the existence of the blood-brain barrier as well as inside of the
blood-brain barrier (McKinley et al., 2003). Recent studies sug-
gest that the systemic administered AT1 receptor blockers also
act on the AT1 receptor within the brain, thereby reducing blood
pressure in hypertensive rats (Tsuchihashi et al., 1999; Leenen and
Yuan, 2001; Lin et al., 2005; Araki et al., 2009; Hirooka et al.,
2010; Kishi et al., 2012b; Konno et al., 2012). The extent of the
actions of AT1 receptor blockers within the brain might depends
partly on the lipophilicity and pharmacokinetics (Gohlke et al.,
2001; Wang et al., 2003). Sympathoinhibitory effect via reduc-
tion of oxidative stress through the inhibition of the AT1 receptor
in the brain is differed between AT1 receptor blockers. Orally
administered telmisartan or olmesartan reduced blood pressure
and urinary norepinephrine excretion in SHRSPs, and it was
associated with a reduction of oxidative stress production in
the brainstem including the RVLM (Araki et al., 2009; Hirooka
et al., 2010). Orally administered telmisartan could inhibit AT1
receptor-induced oxidative stress in the RVLM and activation of
the SNS in SHRSPs to a greater extent than candesartan, in spite of
similar depressor effects (Kishi et al., 2012b). In obesity-induced
hypertensive rats, telmisartan could also inhibit AT1 receptor-
induced oxidative stress in the RVLM and activation of the SNS to
a greater extent than losartan, in spite of similar depressor effects
(Konno et al., 2012). Thus, it is conceivable that orally adminis-
tered AT1 receptor blockers might block the AT1 receptor in the
brain, particularly in the RVLM, thereby reducing the oxidative
stress production and reducing blood pressure via inhibiting the
activation of the SNS.
SYMPATHOINHIBITION BY TARGETING BRAIN OXIDATIVE
STRESS IN HYPERTENSION
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) are potent inhibitors of cholesterol biosynthesis.
Interestingly, a previous study suggests that statins reduce
blood pressure in patients with hypertension (Golomb et al.,
2008). Moreover, the potential sympathoinhibition of statins
has been demonstrated (Kishi et al., 2003; Sinski et al.,
2009; Gomes et al., 2010; Kishi and Hirooka, 2010; Siddiqi
et al., 2011). It has been demonstrated that statins have anti-
oxidant effect (Wassmann et al., 2002). We have demonstrated
that orally administered atorvastatin causes sympathoinhibition
and improves the impaired baroreflex sensitivity via reduction
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of oxidative stress through the inhibition of AT1 receptor-NAD
(P) H oxidase and up-regulation of MnSOD in the RVLM of
SHRSPs (Kishi et al., 2008, 2009, 2010b). Other previous stud-
ies have demonstrated that simvastatin normalized the activation
of the SNS in rabbits with heart failure (Pliquett et al., 2003;
Gao et al., 2005). However, it has not been fully clarified whether
the statin-induced sympathoinhibition via reduction of oxidative
stress in the brain is a class-effect or not.
Several calcium channel blockers have been confirmed to cause
sympathoinhibition via reduction of oxidative stress in hyperten-
sive rats. Orally administered amlodipine (Hirooka et al., 2006)
or azelnidipine (Konno et al., 2008) cause sympathoinhibition
via reduction of oxidative stress in the RVLM of SHRSPs. We
confirmed that orally administered azelnidipine inhibit the NAD
(P) H oxidase activity and activate MnSOD in the RVLM of
SHRSPs (Konno et al., 2008). These results are consistent with
previous study (Umemoto et al., 2004). Furthermore, combina-
tion of atorvastatin and amlodipine (Kishi and Sunagawa, 2012)
or combination of olmesartan and azelnidipine (Shinohara et al.,
2012) has additive effects of sympathoinhibition via reduction of
oxidative stress in the brain.
Interestingly, calorie restriction (Kishi et al., 2011a) or exer-
cise training (Kishi et al., 2012a) has a pivotal role to cause
sympathoinhibition via reduction of oxidative stress through the
inhibition of the AT1 receptor in hypertensive rats. These results
provide us the possibility that adipocytokines and/or insulin
resistance might affect the brain AT1 receptor, and cause sympa-
thoexcitation.
PERSPECTIVES
Figure shows our concept in the regulation of the activation
of the SNS via brain renin-angiotensin system and oxidative
stress (Figure 1). In the brain, particularly in the autonomic
regulatory regions, such as the RVLM, NTS and PVN of the
hypothalamus, previous studies have suggested that the inhibi-
tion of the brain AT1 receptor may have a significant role in the
sympathoinhibitory effect via reduction of oxidative stress. AT1
receptor blockers are widely used in the treatments for hyper-
tension (Iwanami et al., 2009). It is also suggested that AT1
receptor blockers may have protective effects on neurons, reduc-
ing the incidence of stroke and improving cognition (Iwanami
et al., 2009; Mogi and Horiuchi, 2009). In addition, renal affer-
ent nerves may also contribute to the blood pressure elevation
according to the recent findings of the renal nerve ablation in
FIGURE 1 | A schema showing our concept in the regulation of
sympathetic nerve activity via brain renin-angiotensin system and
oxidative stress.
patients with resistant hypertension (Krum et al., 2009; DiBona
and Esler, 2010; Simplicity HTN-2 Investigators, 2010). Renal
afferent nerves project directly into many areas in the central ner-
vous system controlling the activation of the SNS such as the
NTS and hypothalamus (Calaresu and Ciriello, 1981; Ciriello and
Calaresu, 1983; Stella et al., 1987). It is demonstrated that oxida-
tive stress mediates the stimulation of the SNS in the phenol renal
injury model of hypertension in which the renal afferent nerves
are stimulated (Ye et al., 2006). In this model, brain AT1 receptor
and NAD (P) H oxidase are activated. Previous studies have sug-
gested that the increased oxidative stress production and reduced
neuronal NOS expression may be involved in this mechanisms,
which leads to the alteration of cytokines in the brain (Campese
et al., 2005; Ye et al., 2006). It is interesting and important to con-
sider that AT1 receptor and related oxidative stress production in
the brain are as novel therapeutic targets of the treatments for
hypertension.
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